Ironwood Pharmaceuticals | IRWD - Interest Expense On Debt


Ironwood Pharmaceuticals reported $8.74M in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Akebia Therapeutics 349.66M 12.86M Jun/2026
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
Amarin USD 3K 5K Dec/2024
Ardelyx USD 4.96M 642K Jun/2026
Astellas Pharma JPY 3.91B 320M Mar/2025
AstraZeneca USD 371M 31M Sep/2026
Charles River Laboratories USD 30.34M 3.6M Jun/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Incyte USD 605K 23K Sep/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
MacroGenics USD 4.4M 493K Jun/2026
Moderna USD 10.96B 527M Jun/2026
Myriad Genetics USD 4.4M 600K Dec/2025
Pacira USD 3.62M 77K Jun/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Takeda JPY 63.38B 466M Sep/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025